These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 12958779)

  • 1. [Classifying and treating rheumatoid pain. 5 questions point to the diagnosis].
    Märker-Hermann E; Bauer H
    MMW Fortschr Med; 2003 Jul; 145(29-30):47-50. PubMed ID: 12958779
    [No Abstract]   [Full Text] [Related]  

  • 2. [Rheumatic diseases in old age].
    Klein G
    Wien Med Wochenschr; 1975 Mar; 125(12):182-5. PubMed ID: 769355
    [No Abstract]   [Full Text] [Related]  

  • 3. [Rheumatology update--1. Summary of clinically significant current knowledge and outlook perspective of relevant trends in etiopathogenetic research, diagnostic methods and therapeutic possibilities].
    Hein G; Bolwin R; Bräuer R; Eidner T; Franke S; Oelzner P; Sprott H
    Med Klin (Munich); 1995 Apr; 90(4):231-9. PubMed ID: 7776937
    [No Abstract]   [Full Text] [Related]  

  • 4. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
    Mariette X
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pain therapy in rheumatism. After 65 years of age coxibs are the best choice].
    MMW Fortschr Med; 2003 Oct; 145(42):60. PubMed ID: 14655447
    [No Abstract]   [Full Text] [Related]  

  • 6. [Rheumatic manifestations--when and how to treat?].
    Schattenkirchner M
    Verh Dtsch Ges Inn Med; 1990; 96():95-105. PubMed ID: 2092519
    [No Abstract]   [Full Text] [Related]  

  • 7. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
    [No Abstract]   [Full Text] [Related]  

  • 8. [Rheumatism--current state of the problem].
    Nasonova VA
    Klin Med (Mosk); 1991 May; 69(5):115-21. PubMed ID: 1857065
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis.
    Bliddal H; Terslev L; Qvistgaard E; Konig M; Holm CC; Rogind H; Boesen M; Danneskiold-Samsøe B; Torp-Pedersen S
    Scand J Rheumatol; 2006; 35(5):341-5. PubMed ID: 17062431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
    Baslund B; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biologics].
    Kalden JR
    Z Rheumatol; 2016 Aug; 75(6):604-10. PubMed ID: 27365024
    [No Abstract]   [Full Text] [Related]  

  • 12. [Use of a new antirheumatic drug: midalgyl].
    Vignon G; Laurent J; Kopp N
    Presse Med (1893); 1970 Nov; 78(48):2145-6. PubMed ID: 5312370
    [No Abstract]   [Full Text] [Related]  

  • 13. [Rheumatology update--II. Summary of clinically significant current knowledge and outlook of prospective relevant trends in etiopathogenic research, diagnostic methods and therapeutic possibilities].
    Hein G; Bolwin R; Bräuer R; Eidner T; Franke S; Oelzner P; Sprott H
    Med Klin (Munich); 1996 Apr; 91 Suppl 1():56-64. PubMed ID: 8657087
    [No Abstract]   [Full Text] [Related]  

  • 14. [Evidence based medicine in rheumatology].
    Gause A; Raspe HH
    Z Rheumatol; 2002 Oct; 61(5):516-8. PubMed ID: 12399877
    [No Abstract]   [Full Text] [Related]  

  • 15. [Not Available].
    Krüger K
    Dtsch Med Wochenschr; 2017 Nov; 142(23):1773-1774. PubMed ID: 29145683
    [No Abstract]   [Full Text] [Related]  

  • 16. [Fetal safety profile of drugs used in the treatment of inflammatory rheumatic diseases].
    Falcão S; Mourão AF; Pimentão JB; Branco JC
    Acta Reumatol Port; 2007; 32(4):323-31. PubMed ID: 18159198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Extraintestinal manifestations in inflammatory bowel disease].
    Larsen S; Bendtzen K; Nielsen OH
    Ugeskr Laeger; 2009 Oct; 171(43):3078-83. PubMed ID: 19852894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
    [No Abstract]   [Full Text] [Related]  

  • 19. Juvenile spondyloarthropathies: inflammation in disguise.
    Akin E
    Minn Med; 2009 Sep; 92(9):45-7. PubMed ID: 19877479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research on the antirheumatic action of a new nonsteroid antiphlogistic drug, butoxyphenyl-acethydroxamic acid].
    Spotorno N; Viara M
    Reumatismo; 1968; 20(2):172-5. PubMed ID: 5311717
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.